Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 12/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 4/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ALDH3A1 | P30838 | 5/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399999 | 1.00 | NOD1 (1.00) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL14247143 | 0.88 | NOD1 (1.00) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL8042793 | 0.82 | ALDH3A1 (0.74) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL28449805 | 0.82 | ALDH3A1 (0.74) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL28309197 | 0.81 | ALDH3A1 (0.72) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL21066371 | 0.81 | NOD1 (0.67) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL16671930 | 0.78 | NOD1 (0.70) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL4873241 | 0.78 | NOD1 (0.66) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL21349201 | 0.77 | ALDH3A1 (0.66) | NOD1CXCL8NOD2GAAALDH3A1 | |
| SCHEMBL28144731 | 0.77 | ALDH3A1 (0.65) | NOD1CXCL8NOD2GAAALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021198511-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SARS-COV-2 INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-10-07 | — | — | WO | claimed |
| WO-2016160880-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | claimed |
| US-20230277559-A1 | Compositions and Methods for the Treatment of Inflammation in Urological Pathology | DUKE UNIVERSITY (US) | 2023-09-07 | — | — | US | disclosed |
| US-11559536-B2 | Compositions and methods for the treatment of inflammation in urological pathology | DUKE UNIVERSITY (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | disclosed |
| US-20200368257-A1 | Compositions and Methods for the Treatment of Inflammation in Urological Pathology | DUKE UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| WO-2020212484-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-10-22 | — | — | WO | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| WO-2016160880-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATITIS | BAYLOR RESEARCH INSTITUTE (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| WO-2015023958-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015003246-A1 | COMBINATION OF A STATIN WITH AN INFLAMMASOME INHIBITOR | MCMASTER UNIVERSITY (CA) | 2015-01-15 | — | — | WO | disclosed |
| US-20120046329-A1 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-02-23 | — | — | US | disclosed |
| US-20120046329-A1 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-02-23 | — | — | US | disclosed |
| WO-2012021647-A2 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | NOD1 13/4885CXCL8 26/4885NOD2 12/4885 |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | NOD1 207/4885CXCL8 1185/4885NOD2 96/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | NOD1 13/4885CXCL8 26/4885NOD2 12/4885 |
| US-20120046329-A1 | MODULATORS OF NOD1 AND NOD2 SIGNALING, METHODS OF IDENTIFYING MODULATORS OF NOD1 AND NOD2 SIGNALING, AND USES THEREOF | NOD2, NOD1, NLRP1 | NOD1 2/4885CXCL8 199/4885NOD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.